Advances in Formulation Strategies of Floating Microspheres for Gastroretentive Drug Delivery – A Review Article

Gastroretentive drug delivery systems (GRDDS) are designed to get around issues like short GRT and rapid gastric emptying, which lower the bioavailability of medications that are mostly absorbed in the proximal small intestine or stomach [1]. Low-density systems known as floating microspheres, a multi particulate GRDDS, float on gastric fluid to provide extended drug release, improved absorption, and a lower frequency of dosage [2]. Uniform drug distribution, low local irritation, and adaptability in encapsulating hydrophilic and hydrophobic drugs are some of their benefits [3]. In order to address physiological and technological challenges, this review offers a thorough examination of formulation strategies, mechanisms, evaluation methods, and therapeutic applications.

2. Mechanism of gastro retention

By maintaining a density below that of gastric fluid (roughly 1.004–1.01 g/cm2), floating microspheres accomplish gastric retention through buoyancy [3].

Among the primary mechanisms are:

• Non-effervescent Systems: To provide buoyancy without producing gas, these systems use hollow microsphere structures or naturally low-density polymers (such as ethyl cellulose or Eudragit®) [4]. Microspheres can float for up to 24 hours because of the hollow core that is created during preparation, which lowers density [4]. For medications that need stable, non-reactive environments, these systems are perfect.
• Effervescent Systems: These use gas-generating substances, like calcium carbonate or sodium bicarbonate, which react with stomach acid to produce CO? and produce gas bubbles that improve flotation [5]. As demonstrated by norfloxacin formulations containing 10–15% sodium bicarbonate, the gas entrapment within the polymer matrix guarantees prolonged buoyancy [20]. Because the pH of the stomach is lower in fed states, effervescent systems work especially well [5].
• Hybrid Systems: These systems improve retention by sticking to the stomach mucosa while retaining buoyancy by combining floating and bio adhesive qualities [14]. For example, HPMC microspheres coated with chitosan improve GRT by providing both flotation and mucoadhesion [14].

Because of these mechanisms, which guarantee consistent release profiles, lessen gastric irritation, and ensure uniform drug distribution, floating microspheres are appropriate for medications such as amoxicillin and metformin [6].

3. Formulation Strategies

To achieve the required buoyancy, drug encapsulation, and release kinetics, the development of floating microspheres necessitates careful optimisation of formulation variables, polymer selection, and preparation methods. Below is a summary of recent developments.

3.1 Methods of Preparation

The size, porosity, buoyancy, and drug release properties of microspheres are determined by the preparation method used. Advanced methods consist of:

3.1.1 Emulsion-Solvent Evaporation/Diffusion

Due to its ability to control microsphere properties, this adaptable technique is widely used [7].

The procedure entails:

• Dissolving the medication and polymer (such as ethyl cellulose or Eudragit® RS) in an organic solvent (such as ethanol, dichloromethane or acetone)
• To create an oil-in-water emulsion, the organic phase is emulsified in an aqueous phase that contains a surfactant (such as 0.5–2% polyvinyl alcohol, or PVA).
• To create hollow or porous microspheres, the solvent is evaporated under carefully regulated conditions (e.g., 25 - 40°C, 800-1600 rpm stirring)

For instance, micro balloons loaded with tranilast and ibuprofen made using this technique demonstrated encapsulation efficiencies of 80–85% while maintaining buoyancy for more than 12 hours [8]. By varying the solvent ratios (such as ethanol:dichloromethane 1:1) and stirring speed, the technique enables fine-tuning of particle size (10–100 µm) and porosity [18]. It is suitable for both hydrophilic and hydrophobic drugs but requires careful solvent selection to avoid toxicity [7].

3.1.2 Spray Drying

By atomising a drug-polymer solution into a hot air stream (120–150°C), spray drying creates microspheres by quickly evaporating the solvent to create porous or hollow structures [9].

Important characteristics include:

• Quick production with consistent 5–50 µm particle sizes
• Adequacy for water – soluble medications, such as 5 – fluorouracil (5-FU), with 70 – 75% encapsulation efficiencies [9].
• The production of low density microspheres using polymers such as PLGA, ethyl cellulose or HPMC

In order to improve buoyancy and drug entrapment, recent optimisations have involved modifying the nozzle size, feed rate, and inlet temperature [9]. For example, spray-dried metformin microspheres demonstrated high buoyancy and sustained release over a 10-hour period [26]. Although the technique is scalable, heat-stable medications and polymers are needed [9].

3.1.3 Ionotropic Gelation

This environmentally friendly technique creates floating beads by cross-linking natural polymers, such as sodium alginate, with divalent cations, such as calcium chloride, which ranges from 2 to 10% w/v [10].

The drug and polymer are dissolved in an aqueous solution, and the solution is then dropwise extruded into a cross-linking bath to create gelled microspheres.

Due to the pH-dependent gelation of alginate, ritonavir hollow microballoons made by ionotropic gelation demonstrated buoyancy for 10–12 hours and sustained release [10]. Because the technique doesn't use organic solvents, it can be used with biodegradable formulations and medications that are sensitive to acid.

To maximise bead strength and buoyancy, parameters such as cross-linking time (5–30 minutes) and alginate concentration (1–3% w/v) are essential [10].

3.1.4 Sublimation Technique

In order to produce porous, low-density structures, this method introduces sublimating agents (such as menthol, camphor, or ammonium carbonate) into the microsphere matrix, which are then eliminated after compression or drying [11]. For instance, the highly porous architecture of menthol-containing cilostazol gastroretentive tablets resulted in improved buoyancy [11].

Among the main benefits are:

• Scalability for industrial applications;
• Simplified processing with minimal equipment.
• The capacity to construct structures with ultra-low densities (less than 0.9 g/ cm³)

For medications that need high buoyancy and few processing steps, the sublimation method works especially well [11].

3.1.5 Electro spraying

Electro spraying creates homogeneous microspheres with regulated porosity by atomising polymer-drug solutions using an electric field [26].

The method involves :

• Applying a high voltage (10–20 kV) to a polymer-drug solution that has been extruded through a needle is one step in the procedure.
• Gathering microspheres with sizes ranging from 1 to 50 µm on a grounded plate.

Because of their uniform particle size and porosity, metformin-loaded microspheres made by electro spraying demonstrated a high encapsulation efficiency (up to 90%) and sustained release [26]. Although it necessitates specific equipment, this technique is becoming more popular for precision formulations [26].

3.1.6 Hot-Melt Extrusion

To create microspheres with consistent drug distribution, hot-melt extrusion mixes drug and polymer at high temperatures (80–150°C) [30]. It achieves high entrapment and controlled release, making it appropriate for poorly soluble medications such as carvedilol [17]. Although the technique is scalable, heat-stable components are needed [30].

3.1.7 Supercritical Fluid Technology

This technique produces low-density, high-porosity microspheres by using supercritical CO? as a solvent or antisolvent [32]. Due to the solvent-free method and exact control over particle shape, levodopa-loaded microspheres made using this technique demonstrated exceptional buoyancy and sustained release [32]. Although it requires high-pressure equipment, the method is environmentally friendly [32].

3.2 Polymer Selection

Polymers play a key role in regulating mucoadhesion, buoyancy, and drug release. Recent developments consist of:

3.2.1 Hydrophilic Polymers

When hydrated, hydrophilic polymers such as sodium alginate, hydroxypropyl methylcellulose (HPMC), and hydroxypropyl cellulose (HPC) create a gel layer that improves buoyancy and regulates drug release [12].

As an illustration,

• HPMC K15M in miglitol microspheres produced a 98.84% drug release over 12 hours and maintained buoyancy for 14 hours [13].
• As demonstrated by norfloxacin beads, sodium alginate creates a buoyant matrix in acidic gastric fluid [20].
• For medications that need rapid or sustained release, HPC offers flexibility in release profiles [12].

Advantages:

• Biocompatibility: Low toxicity and safe for oral administration [12].
• Gel-Forming Ability: Increases buoyancy and maintains drug release by causing swelling [12].
• Versatility: Adaptable to both non-effervescent and effervescent systems [12].
• Cost-Effectiveness: Economical and widely accessible for large-scale manufacturing [13].

Disadvantages:

• Moisture Sensitivity: Needs careful storage because it degrades easily in humid environments [12].
• Variable Release Profiles: Reproducibility may be impacted by swelling behaviour that varies with gastric Ph and food intake [12].
• Limited Mucoadhesion : For improved retention, more bioadhesive polymers might be needed [14].

3.2.2 Bioadhesive Polymers

By sticking to the stomach mucosa, bioadhesive polymers such as chitosan and Carbopol® improve gastric retention [14]. Trimetazidine dihydrochloride microspheres based on chitosan demonstrated buoyancy and sustained release for ten hours [14]. As demonstrated in amoxicillin formulations, Carbopol® enhances retention by forming a hydrogen bond with mucin [27].

Advantages:

• Improved Retention: Prolonged GRT due to strong mucoadhesion increases bioavailability [14].
• Biocompatibility: Chitosan is safe for oral use and biodegradable [14].
• pH-Dependent Properties: Chitosan performs better in gastric conditions because it dissolves in acidic environments [14].
• Antimicrobial Properties: Formulations that target H. pylori benefit from chitosan's natural antimicrobial activity [27].

Disadvantages:

• pH Sensitivity: The solubility of chitosan diminishes at neutral pH, restricting its release in the small intestine [14].
• Complex Processing : During preparation, cross-linking and pH must be carefully controlled [14].
• Possible Irritation: Sensitive patients may experience mucosal irritation from high Carbopol® concentrations [27].

3.2.3 Enteric Polymers

Acid-labile medications are protected in the stomach and released in the small intestine's neutral pH by enteric polymers such as cellulose acetate and Eudragit® (L100, S100, RS), which offer pH-dependent release [15]. In cimetidine microspheres, for instance, Eudragit® RS guaranteed release at pH 6.8 [22].

Advantages:

• pH-Dependent Release: Targets release in particular GIT regions and protects medications that are sensitive to acid [15].
• Controlled Release: Sustained release profiles are offered by Eudragit® RS and RL grades [15].
• Stability: Preserves drug integrity in gastric fluid by resisting acidic degradation [15].

Disadvantages:

• Limited Buoyancy: Unless paired with low-density polymers, higher density may decrease floatation [15].
• Cost: Higher formulation costs compared to hydrophilic polymers [15].
• Complex Compatibility: To prevent interactions with other formulation components, careful selection is necessary [15].

3.2.4 Natural and Biodegradable Polymers

Because of their low toxicity and biocompatibility, natural polymers such as guar gum, zein, and alginate are preferred [16]. Longer GRT was attained by zein-based floating tablets [16]. Ionotropic gelation makes extensive use of alginate [10].

Advantages:

• Biodegradability: Safe for extended use and kind to the environment [16].
• Low Toxicity: Few adverse effects, increasing patient adherence [16].
• Versatility: Zein works well with sublimation methods, whereas alginate facilitates ionotropic gelation [10, 16].
• Economical: Easily obtainable from natural sources [16].

Disadvantages:

• Mechanical Weakness: In extremely acidic environments, alginate beads may break down [10].
• Variable Purity: Because of source variability, natural polymers may exhibit irregularities in their properties [16].
• Restricted Release Control: For exact release profiles, synthetic polymers might be needed [16].

3.2.5 Smart Polymers

Adaptive drug release is made possible by stimuli-responsive polymers, such as pH-sensitive Eudragit® grades and poly(N-isopropylacrylamide) (PNIPAAm) [33]. The release of PNIPAAm microspheres is regulated by the temperature of the stomach [33].

Advantages:

• Adaptive Release: Improves targeting by reacting to enzymatic, pH, or temperature stimuli [33].
• Precision: Increases the effectiveness of medication delivery under particular circumstances [33].
• Innovation Potential: Fit for cutting-edge uses such as chronotherapy [33].

Disadvantages:

• Complexity: Advanced knowledge is needed for synthesis and incorporation [33].
• Cost: Scalability is constrained by high production costs [33].
• Stability Issues: Shelf life may be impacted by sensitivity to environmental factors [33].

3.3 Optimization of Formulation Variables

Achieving the intended microsphere characteristics, such as buoyancy, encapsulation effectiveness, and drug release kinetics, requires careful optimisation of formulation variables. With the aid of sophisticated methods and statistical tools, the ensuing sections offer a more thorough examination of important variables and their optimisation strategies.

3.3.1 Polymer Concentration

Drug entrapment, matrix strength, and microsphere viscosity are all strongly impacted by polymer concentration [17]. By creating a strong matrix, higher concentrations (2–5% w/v) increase viscosity, improving encapsulation efficiency and extending drug release [17].

• For instance, 90% encapsulation efficiency and sustained release over 12 hours were attained by carvedilol microspheres made with 3% ethyl cellulose using a 3² full factorial design [17]. Weak matrices produced by concentrations below 1% decreased encapsulation and buoyancy [17].
• In miglitol microspheres, HPMC K15M at 2–4% w/v guaranteed 98.84% drug release and 14-hour buoyancy [13]. Density rose with higher concentrations (>5%), impairing flotation [13].

Optimization Strategies:

• Response Surface Methodology (RSM): This technique is used to simulate how polymer concentration affects responses such as release rate and encapsulation efficiency [17]. The ideal HPMC concentrations (2.5–3.5%) for metformin microspheres were determined by central composite designs [26].
• Viscosity Measurements: To guarantee ideal droplet formation during emulsification, rheometers measure the viscosity of polymer solutions [17]. For example, solutions containing 3% ethyl cellulose maintained viscosities between 100 and 200 mPa·s, which is perfect for homogeneous microspheres [17].
• Trade-off Analysis: Takes buoyancy and encapsulation efficiency into account. Density is increased by too much polymer, so factorial designs are required for optimisation [17].

3.3.2 Solvent Ratios

In emulsion-solvent evaporation, the proportion of organic solvents (such as ethanol: dichloromethane) influences the buoyancy, porosity, and morphology of microspheres [18].

Uniform droplet formation and solvent evaporation are guaranteed by a balanced ratio:

• Spherical ibuprofen microspheres with ideal buoyancy and 85% encapsulation efficiency were created using a 1:1 ethanol:dichloromethane ratio [18]. Due to drug partitioning into the aqueous phase, a higher dichloromethane content (1:1.5) decreased encapsulation but decreased particle size to 10–20 µm [18].
• The porosity of tranilast microballoons was affected by the acetone:ethanol ratios (1:0 to 1:2), with 1:1 ratios producing extremely porous structures for 12-hour flotation [8].

Optimization Strategies:

• Box-Behnken Design: Assesses impacts on particle size and encapsulation efficiency to optimise solvent ratios [18]. A 1:1 ratio reduced size variation (RSD <5%) for ibuprofen [18].
• Solvent Volatility: Choosing solvents with the right boiling points, such as dichloromethane at 40°C, guarantees quick evaporation without sacrificing the stability of the drug [7].
• Phase Diagram Analysis: This method ensures uniform microsphere formation by mapping solvent interactions to predict emulsion stability [18].

3.3.3 Stirring Speed

Microsphere size, homogeneity, and encapsulation effectiveness are influenced by the speed at which the emulsion is stirred during preparation [19]:

• Alginate microspheres (10–50 µm) with 80–90% encapsulation efficiency were produced at 1000–1200 rpm [19]. Larger, irregular particles were produced at lower speeds (<800 rpm), whereas excessive shear at higher speeds (>1600 rpm) led to drug loss [19].
• A consistent size distribution and 12-hour buoyancy were attained by norfloxacin beads made at 1000 rpm [20].

Optimization Strategies:

• Fractional Factorial Design: Assesses size and encapsulation efficiency to determine the ideal stirring speeds [19]. According to a study on alginate microspheres, 30 µm particles work best at 1100 rpm [19].
• High-Shear Homogenisation: By guaranteeing consistent droplet size in emulsions, high-shear homogenisation lowers polydispersity [19]. HPMC microsphere size variation was reduced by homogenisers running at 1000–1200 rpm [13].
• Real-Time Monitoring: During emulsification, laser diffraction tracks droplet size, enabling dynamic stirring speed adjustment [19].

3.3.4 Gas-Generating Agents

To improve buoyancy in effervescent systems, gas-generating substances such as calcium carbonate or sodium bicarbonate (5–15% w/w) generate CO? [5]:

• Because of ideal gas entrapment, norfloxacin beads containing 10% sodium bicarbonate stayed afloat for 12-14 hours [20]. Concentrations greater than 15% reduced buoyancy by compromising matrix integrity [20].
• In metformin microspheres, calcium carbonate (8% w/w) guaranteed 10-hour flotation with a low lag time (<30 seconds) [26].

Optimization Strategies:

• Design of Experiments (DoE): Balances buoyancy and matrix stability by optimising the concentration of gas-generating agents [20]. The ideal sodium bicarbonate range for norfloxacin was found to be 10–12% using a 2² factorial design [20].
• pH-Dependent Gas Generation: Enough CO? is produced when tested in SGF (pH 1.2) [5]. For medications that need to be stable at a neutral pH, calcium carbonate is the preferred option [26].
• Gas Entrapment Efficiency: As observed in alginate beads, SEM analysis measures pore formation to validate gas retention [10].

3.3.5 Surfactant Concentration

Emulsions are stabilised by surfactants such as PVA or Tween 80 (0.5–2% w/v), which guarantee consistent droplet formation [24]:

• Curcumin microspheres with 1% PVA had a consistent size of 20–30 µm and an encapsulation efficiency of 85% [24]. Concentrations greater than 2% decreased buoyancy by increasing density [24].
• Tween 80 (0.5%) increased sphericity and emulsion stability in ibuprofen microspheres [18].

Optimization Strategies:

• Central Composite Design: This design maximises the concentration of surfactant for uniform size and encapsulation [24]. 0.8–1.2% PVA maximised EE for curcumin [24].
• Surface Tension analysis: The best surfactant levels are found by measuring emulsion stability using surface tension analysis [24]. For stable emulsions, PVA at 1% decreased surface tension to 40–50 mN/m [24].
• HLB Value Optimisation: Compatibility with drug-polymer systems is ensured by choosing surfactants with the proper hydrophilic-lipophilic balance (HLB) [18].

3.3.6 Drug-to-Polymer Ratio

Entrapment and release kinetics are influenced by the drug-to-polymer ratio (1:1 to 1:5) [26]:

• In metformin microspheres, a 1:3 ratio produced 90% encapsulation and 10-hour sustained release [26]. Because of drug saturation, higher ratios (1:1) decreased encapsulation, whereas lower ratios (1:5) unduly slowed release [26].
• 1:2 ratio carvedilol microspheres that maximise buoyancy and entrapment (88%) [17].

Optimization Strategies:

• Plackett-Burman Design: Drug-to-polymer ratios are screened using the Plackett-Burman Design to find noteworthy effects on EE and release [17]. For carvedilol, a ratio of 1:2.5 was ideal [17].
• Drug Solubility Studies: Prevents phase separation by ensuring compatibility with the polymer matrix [26]. The uniform incorporation at 1:3 was made possible by metformin's high solubility [26].
• Release Modelling: Korsmeyer-Peppas models help choose ratios by forecasting release kinetics [22].

3.3.7 Cross-Linking Agents

Cross-linking agents such as calcium chloride (2–10% w/v) affect the buoyancy and strength of the beads in ionotropic gelation [10]:

• Strong gelation and 12-hour buoyancy were demonstrated by ritonavir microspheres containing 5% calcium chloride [10]. Because of excessive cross-linking, drug release was slowed at concentrations greater than 10% [10].
• In acidic environments, barium chloride (3%) increased the durability of alginate beads [19].

Optimization Strategies:

• Factorial Design: Enhances cross-linking duration and cross-linker concentration [10]. 10-minute cross-linking and 5% calcium chloride were found to be ideal in a ritonavir study [10].
• Gel Strength Testing: To verify mechanical stability, texture analysers gauge bead hardness [10]. Compressive strengths of 0.5–1 N were demonstrated by alginate beads containing 5% calcium chloride [10].
• pH Sensitivity Analysis: Verifies the effectiveness of cross-linking in acidic stomach conditions [10].

3.3.8 pH and Temperature

Drug integrity and microsphere stability are impacted by the drying temperature and the preparation medium's pH [15]:

• Alginate solutions with a pH between 4 and 6 guaranteed the formation of beads without causing drug degradation [10]. Acidic media (pH <4) reduced uniformity by causing premature gelation [10].
• Drug activity was maintained in emulsion methods by drying at 25–50°C [15]. Heat-stable medications, such as 5-FU, were needed for spray drying at 120–150°C [9].

Optimization Strategies:

• pH Titration Studies: Track how pH affects drug stability and polymer solubility [15]. At pH 4.5, alginate microspheres remained intact [10].
• Thermal Analysis: Drug stability at processing temperatures is guaranteed by DSC [15]. When dried at 40°C, metformin did not degrade [26].
• QbD Approach: To ensure robust formulations, Quality-by-Design principles incorporate temperature and pH into risk assessments [34].

3.3.9 Porogen or Sublimating Agent Concentration

Porogens such as ammonium carbonate or menthol form porous structures in sublimation techniques [11]:

• Ultra-low density (<0.9 g/cm³) and improved buoyancy were attained by cilostazol tablets containing 10% menthol [11]. Matrix integrity was compromised at concentrations greater than 15% [11].
• Ammonium carbonate (5–10%) extended flotation by creating extremely porous structures in zein-based tablets [16].

Optimization Strategies:

• Porosity Analysis: Pore size and volume are measured by mercury intrusion porosimetry [11]. With 10% menthol, clostazol tablets exhibited 60% porosity [11].
• Sublimation Kinetics: Controls temperature and time during sublimation to enhance porosity while maintaining structural integrity [11]. It was best to sublimate menthol for six hours at 50°C [11].
• DoE Optimisation: Box-Behnken designs strike a balance between buoyancy, release, and porogen concentration [16].

3.3.10 Emulsion Droplet Size

Droplet size during emulsification influences the size and homogeneity of the final microsphere in emulsion-based techniques [18]:

• Uniform ibuprofen microspheres exhibiting excellent buoyancy were achieved using droplet sizes between 10 and 50 µm [18].Non-spherical particles were produced by larger droplets (>100 µm) [18].
• For curcumin microspheres, high-shear emulsification at 1000 rpm guaranteed droplet sizes of 20–30 µm [24].

Optimization Strategies:

• Dynamic Light Scattering (DLS): This technique ensures uniformity by continuously monitoring droplet size [18]. For ibuprofen emulsions, DLS verified 25 µm droplets [18].
• Emulsifier Type: Non-ionic emulsifiers, such as Span 80, improve the stability of droplets in oil-in-water emulsions [18].
• RSM Modelling: For uniform droplet sizes, RSM modelling optimises emulsification parameters [18].

3.3.11 Drying Conditions

Microsphere stability and morphology are impacted by drying conditions in emulsion or spray drying techniques [9]:

• Uniform 5-FU microspheres were produced by spray drying at an inlet temperature of 130°C and a feed rate of 0.5 mL/min [9]. Drug degradation occurred at temperatures above 150°C [9].
• The porosity and buoyancy of emulsion-prepared microspheres were maintained by vacuum drying them at 40°C [15].

Optimization Strategies:

• Thermal gravimetric analysis: To avoid residual solvent toxicity, Thermal Gravimetric Analysis (TGA) evaluates the effectiveness of solvent removal [15]. For ethyl cellulose microspheres, TGA verified full solvent evaporation at 40°C [15].
• Spray Drying Optimisation: Reduces thermal stress by adjusting feed rates and inlet/outlet temperatures via RSM [9]. Metformin worked best at 135°C and 0.4 mL/min [26].
• Lyophilization: Used to maintain the integrity of heat-sensitive medications while they dry [15].

3.3.12 Statistical and Computational Tools

Optimisation is improved by sophisticated statistical and computational tools:

• Design of Experiments (DoE): Factorial, Box-Behnken, and central composite designs are used to systematically assess variables such as solvent ratio, stirring speed, and polymer concentration [17, 18]. A 3² factorial design was utilized to refine the encapsulation efficiency and release characteristics of carvedilol microspheres [17].
• Artificial Neural Networks (ANN): Model complex variable interactions to predict optimal formulations [34]. For metformin microspheres, ANN forecasted a 1:3 drug-to-polymer ratio and 3% HPMC [26].
• Quality-by-Design (QbD): Assures strong performance by incorporating important quality attributes (such as buoyancy and EE) into formulation development [34]. Critical factors for norfloxacin beads were determined by QbD, and these included stirring at 1000 rpm and 10% sodium bicarbonate [20].

These optimisation techniques guarantee high-performing, repeatable floating microspheres that are suited to particular therapeutic requirements.

3.4 Innovative Approaches

While addressing the drawbacks of conventional techniques, innovative approaches in floating microsphere development seek to improve performance, targeting, and scalability. A more thorough explanation of these innovative tactics can be found below:

3.4.1 Hybrid Systems

To optimise gastric retention, hybrid systems combine floating and bioadhesive qualities [14]. These systems make use of mucoadhesive polymers for extended mucosal attachment and low-density polymers for buoyancy.

Mechanism: GRT of up to 10 hours is achieved by chitosan-coated HPMC microspheres that float on gastric fluid while sticking to the gastric mucosa [14]. In fasted states, the dual mechanism lessens premature emptying [14].

Advantages: Decreased dosing frequency, increased bioavailability, and improved retention under variable gastric conditions [14]. Trimetazidine hybrid microspheres, for instance, demonstrated 30% increased bioavailability and sustained release [14].

Applications: Perfect for medications such as amoxicillin that are used to eradicate H. pylori, where both long-term retention and local action are essential [27].

Innovations: To balance buoyancy and adhesion, recent developments include multilayered coatings (such as chitosan over Eudragit®) [35]. By creating disulphide bonds with mucin, thiolated chitosan improves mucoadhesion and increases retention by 25% [35].

Challenges: The formulation's intricate design and the possibility of mucosal irritation at high concentrations of bio adhesive polymers present challenges [14]. Using DoE to optimise coating thickness and polymer ratios is the main focus of future research [35].

3.4.2 Nanoparticle Integration

Drug targeting, stability, and bioavailability are improved when nanoparticles are added to microspheres [27].

Mechanism: Acid-sensitive medications are shielded by nanoparticles (such as PLGA and chitosan) encapsulated in microspheres, which offer dual-release profiles (immediate and sustained) [27]. By raising the local drug concentration, amoxicillin nanoparticles in alginate microspheres enhanced the eradication of H. pylori [27].

Advantages: Better solubility of poorly soluble medications, protection of biologics (such as peptides), and increased cellular uptake [27]. Levodopa microspheres loaded with nanoparticles had a 35% increase in bioavailability [32].

Applications: Delivering biologics like insulin and focussing on particular stomach areas (such as H. pylori in mucosal layers) [27, 32]. For diagnostic purposes, theranostic applications combine imaging agents and nanoparticles [32].

Innovations: Stability in acidic environments is improved by integrating lipid-based nanoparticles (such as solid lipid nanoparticles, or SLNs) into microspheres [36]. Release kinetics are optimised by core-shell designs that have floating polymers in the shell and nanoparticles in the core [36].

Challenges: High expenses and complicated manufacturing are obstacles. The goal of future studies is to use microfluidics to simplify the synthesis of nanoparticles with consistent particle size [36].

3.4.3 Porous Matrix Design

Low-density, highly buoyant structures are produced by porous matrix designs using porogens or sublimating agents [11].

Mechanism: After post-processing, agents such as ammonium carbonate or menthol are added and eliminated, resulting in pores that lower density (<0.9 g/cm³) [11]. Tablets containing 10% menthol were buoyant for 12 hours [11].

Advantages: Include increased buoyancy, scalability, and ultra-low density [11]. High drug loading is possible with porous matrices without sacrificing flotation [11].

Applications: Drugs requiring prolonged gastric retention time, such as propranolol for hypertension management [25].Effervescent systems can also benefit from porous designs [11]

Innovations: Ammonium bicarbonate and other advanced porogens form interconnected pore networks that enhance buoyancy and gas entrapment [37]. By precisely controlling the pore architecture, 3D printing allows for the customisation of release profiles [37].

Challenges: Matrix integrity is weakened by high porogen concentrations. In order to maximise pore size, future research will concentrate on biodegradable porogens and computational modelling [37].

3.4.4 3D Printing

Customised microsphere architectures for accurate drug release and buoyancy are made possible by 3D printing [32].

Mechanism: To improve buoyancy, microspheres with customised geometries, like hollow or lattice structures, are made using additive manufacturing techniques (such as fused deposition modelling) [32]. Eudragit®-printed levodopa microspheres demonstrated consistent release and flotation for 10 hours [32].

Advantages: Ability to create patient-specific formulations, precise control over size, shape, and porosity, and the integration of several medications [32]. 90% encapsulation efficiency was attained by 3D-printed metformin microspheres [26].

Applications: Include combination treatments (like amoxicillin-clarithromycin) and chronotherapy (like ranitidine for nocturnal acid reflux) [26, 27].

Innovations: Floating and bioadhesive polymers are combined in a single microsphere by multi-material 3D printing [38]. Vat photopolymerization improves uniformity by producing microspheres with submicron accuracy [38].

Challenges: Limited scalability and expensive equipment. Biocompatible resins and affordable printers are the main topics of future research [38].

3.4.5 Microfluidics

Monodisperse microspheres with exact control over size and structure are created by microfluidic systems [32].

Mechanism: Drug-polymer solutions are uniformly dropped into microchannels in microfluidic devices, and these droplets are then solidified into microspheres by solvent evaporation or cross-linking [32]. Microfluidics-produced alginate microspheres had a size range of 10–20 µm and a size variation of less than 5% [32].

Advantages: Include the capacity to encapsulate biologics, high uniformity, and repeatable drug loading (90–95% EE) [32]. Consistent release profiles were demonstrated by microfluidic metformin microspheres [26].

Applications: Theranostic systems with diagnostic agents and the delivery of sensitive medications (like insulin) [32].

Innovations: Core-shell microspheres with discrete drug release zones are made possible by droplet-based microfluidics [39]. Targeting accuracy is improved by integration with nanoparticles [39].

Challenges: Complicated setup and low throughput. Parallelised microfluidic systems for large-scale manufacturing are among the upcoming advancements [39].

3.4.6 Smart Polymer Systems

For adaptive drug release, smart polymers react to environmental cues (such as pH and temperature) [33].

Mechanism: pH-responsive Eudragit® enables targeted drug release in specific gastrointestinal regions, while polymers like PNIPAAm adjust release based on gastric temperature [33]. Chronotherapy was optimised by PNIPAAm microspheres, which released ranitidine at 37°C [33].

Advantages: Better targeting, accurate drug release, and chronotherapy suitability [33]. Omeprazole was shielded from acidic environments by pH-sensitive microspheres [33].

Applications: Applications include acid-labile drug protection and chronotherapeutic delivery (e.g., theophylline for asthma) [26, 33].

Innovations: Disease-specific release is made possible by polymers that respond to multiple stimuli, such as pH and enzymes [40]. For example, H. pylori infections are targeted by enzyme-responsive chitosan microspheres [40].

Challenges: High expenses and complicated synthesis are obstacles. Stability testing and scalable synthesis are the main areas of future research [40].

3.4.7 Self-Assembling Systems

Self-assembling systems create microspheres through molecular interactions without the need for outside processing [41].

Mechanism: Drugs are encapsulated during the self-assembly of lipids or amphiphilic polymers into microspheres in aqueous media [41]. 85% EE and 8-hour buoyancy were attained by chitosan-lipid microspheres [41].

Advantages: Being biocompatible, solvent-free, and appropriate for biologics [41]. Peptides were shielded from stomach breakdown by self-assembled insulin microspheres [41].

Applications: Includes the delivery of sensitive medications and biologics, such as vaccines [41].

Innovations: Biocompatible microspheres with customised release are produced by peptide-based self-assembly [41]. Targeting is improved by stimuli-responsive self-assembling systems [41].

Challenges: Limited scalability and size control. Computational modelling will be used in future studies to optimise assembly conditions [41].

3.4.8 Magnetic-Responsive Systems

External control of retention and release is made possible by magnetic nanoparticles embedded in microspheres [42].

Mechanism: By reacting to external magnetic fields, iron oxide nanoparticles (FeO?) in microspheres improve gastric retention [42]. Targeted release 6-hour GRT was attained by magnetic amoxicillin microspheres [42].

Advantages: Includes improved targeting, theranostic potential, and precise control over retention [42]. Real-time tracking is made possible by magnetic microspheres that are compatible with MRI [42].

Applications: Applications include H. pylori infections and targeted delivery for stomach cancers [42].

Innovations: Superparamagnetic nanoparticles increase low-intensity field responsiveness [42]. Magnetic retention and buoyancy are combined in hybrid magnetic-floating systems [42].

Challenges: Challenges include high expenses and safety issues with magnetic particles. Regulatory approval and biocompatible coatings are the main topics of future research [42].

3.4.9 Bioinspired Designs

To improve microsphere performance, bioinspired designs imitate natural systems [43].

Mechanism: Ultra-low-density microspheres are made from structures modelled after marine life, such as the buoyancy of jellyfish [43]. Densities of less than 0.8 g/cm³ were attained by alginate microspheres that resembled diatoms [43].

Advantages: Increased sustainability, biocompatibility, and buoyancy [43]. Costs are decreased by using fewer polymers in bioinspired designs [43].

Applications: Applications include environmentally friendly formulations and the delivery of sensitive medications [43].

Innovations: Flotation is improved by biomimetic porous structures that use natural templates, such as pollen grains [43]. Drug stability is increased by enzyme-mimicking coatings [43].

Challenges: Scale-up and complex design present challenges. Future studies investigate mass production templating methods [43].

By providing improved accuracy, targeting, and patient-specific solutions, these cutting-edge techniques overcome the drawbacks of conventional techniques. Clinical translation, cost reduction, and scalability will be the main topics of future research.

4. Evaluation of Floating Microspheres

Thorough testing of floating microspheres guarantees that their effectiveness satisfies therapeutic needs. To verify buoyancy, drug release, stability, and in vivo efficacy, the evaluation includes physical, chemical, and biological tests. An extended explanation of assessment techniques is provided below:

4.1 Buoyancy Studies

In order to simulate stomach conditions, buoyancy is measured in vitro using simulated gastric fluid (SGF, pH 1.2, 0.1 N HCl) [21]. Important parameters consist of:

• Floating Time: For optimal formulations, the microspheres stay afloat for 12 to 24 hours [21]. To replicate gastric motility, tests are carried out in a USP dissolution apparatus II at 37°C with mild agitation (50–100 rpm) [21]. For instance, 10% sodium bicarbonate-containing norfloxacin beads maintained their buoyancy for 14 hours [20].
• Floating Lag Time: The ideal time for microspheres to rise to the surface is less than one minute [21]. Microsphere porosity, gas-generating agent concentration, and polymer density all affect lag time [5]. Because effervescent systems generate CO? more quickly, they exhibit shorter lag times (10–30 seconds) [5].
• Percentage Buoyancy: The percentage of microspheres that float after a predetermined amount of time, such as 12 hours; for formulations that work, this is usually greater than 80% [21]. This is computed by comparing the number of floating microspheres in SGF to the total number of microspheres [21]. After 12 hours, curcumin microspheres had 85% buoyancy [24].

More sophisticated methods include simulating fed and fasted states by measuring buoyancy under different pH levels (1.2–4.0) or tracking flotation dynamics with a high-speed camera [29]. Robustness across physiological conditions is ensured by these studies.

4.2 Drug Release Studies

Using USP apparatus II (paddle type) at 37°C and 50–100 rpm in SGF or pH 6.8 buffer to mimic gastric and intestinal conditions, in vitro dissolution studies assess drug release kinetics [22]. Important elements consist of:

• Release Profile: Establishes whether the release is governed by Hixson-Crowell (erosion-based), first-order (concentration-dependent), or zero-order (constant rate) kinetics [22]. For sustained delivery, cimetidine microspheres demonstrated zero-order release over an 8-hour period [22].
• Cumulative Drug Release: The percentage of drug released gradually; for controlled-release formulations, this is usually 80–100% over 8–12 hours [13]. Over a 12-hour period, miglitol microspheres had a 98.84% release [13].
• Release Mechanism: Diffusion, swelling, or erosion-driven release were examined using mathematical models (such as Korsmeyer-Peppas) [22]. Diffusion-driven release is demonstrated by Eudragit® systems, whereas swelling-controlled release is demonstrated by HPMC-based microspheres [15].

To evaluate pH-dependent release, which is crucial for enteric-coated microspheres, dissolution tests are carried out in a variety of media (pH 1.2, 4.5, 6.8) [15]. To guarantee precise release profiles, sink conditions are preserved [22].

4.3 Particle Size and Morphology

For buoyancy and drug release, particle size and shape are crucial:

• Particle Size: Optimal sizes fall between 1 and 1000 µm and can be determined by sieve analysis or laser diffraction [23]. While larger sizes (500–1000 µm) improve drug loading but may decrease flotation, smaller sizes (10–50 µm) increase buoyancy [23]. For best results, metformin microspheres had an average size of 50 µm [26].
• Morphology: Spherical shape and porous or hollow structures are confirmed by scanning electron microscopy (SEM) [23]. Carvedilol microspheres' homogeneous, porous surfaces were visible in SEM images, which was consistent with their high buoyancy [17].
• Surface Characteristics: Surface roughness and porosity, which affect drug release and buoyancy, are evaluated using SEM or atomic force microscopy (AFM) [23]. Flotation is improved by porous structures, like those found in cilostazol tablets [11].

To guarantee uniformity, the particle size distribution is examined using a Malvern Mastersizer; systems with polydispersity indices less than 0.3 are considered monodisperse [23].

4.4 Encapsulation Efficiency

The percentage of drug entrapped in microspheres is measured by encapsulation efficiency (EE), which is normally between 70 and 92 percent [24].

• UV-Visible Spectroscopy :For medications with a distinct absorbance (such as curcumin at 425 nm), it is ascertained using UV-visible spectroscopy [24]. 85% EE was attained by curcumin microspheres using optimised polymer ratios [24].
• High-Performance Liquid Chromatography (HPLC): For accurate measurement, particularly of medications with low concentrations [24]. Using HPLC, Ritonavir micro balloons displayed 80% EE [10].
• Calculation: The formula is EE = (Actual drug content / Theoretical drug content) × 100. EE is influenced by variables such as drug solubility and polymer concentration [17].

Low EE could be a sign of drug loss during preparation, necessitating stirring speed or solvent ratio optimisation [18].

4.5 Drug Content Uniformity

For reproducible release, content uniformity is essential because it guarantees uniform drug distribution within microspheres [24]. It is evaluated by:

• Sampling: Using UV spectroscopy or HPLC to analyse several batches of microspheres [24].
• Acceptance Criteria: Uniformity is indicated by a relative standard deviation (RSD) of less than 5% [24]. RSD for amoxicillin beads was less than 3%, guaranteeing reliable dosage [27].
• Dissolution Correlation: Consistent release profiles are correlated with uniformity [22].

Inadequate mixing or phase separation during preparation can lead to non-uniformity [18].

4.6 In Vivo Performance

Drug absorption and gastric retention are confirmed by in vivo research:

• Gamma Scintigraphy: Verifies GRT of 4–8 hours in human volunteers by tracking radiolabelled microspheres (e.g., with technetium-99m) [25]. In fed states, propranolol HCl tablets exhibited 6-hour retention [25].
• Magnetic Resonance Imaging (MRI): Verifies buoyancy and retention by visualising the distribution of microspheres in the stomach [25]. Uniform gastric distribution was found in metformin microsphere MRI studies [26].
• Pharmacokinetic Studies: Determine the drug's bioavailability by measuring its plasma levels. When compared to traditional forms, amoxicillin microspheres enhanced bioavailability by 25% [27].
• Animal Models: GRT and drug absorption are assessed in rats or rabbits under carefully monitored circumstances [25]. 5-hour GRT for ofloxacin microspheres was validated in rat studies [28].

Physiological factors such as fed/fasted states and gastric motility are taken into consideration in in vivo studies [25].

4.7 Stability Studies

Stability studies evaluate drug stability and microsphere integrity over a 6-month period at accelerated temperatures (40°C and 75% relative humidity) [15]:

• Physical Stability: Uses buoyancy tests and SEM to assess changes in size, shape, and buoyancy [15]. After six months, microspheres based on Eudragit® retained >80% buoyancy [15].
• Chemical Stability: Uses HPLC to measure drug content and identify degradation [15]. After six months, cimetidine microspheres showed less than 2% drug loss [22].
• Microbial Stability: Tests for microbial growth to ensure safety, especially for natural polymers like alginate [10].

Stability is critical for shelf-life determination and regulatory compliance [15].

4.8 Swelling Index

The swelling index calculates how much water hydrophilic polymers (like alginate and HPMC) absorb, which affects buoyancy and release [12]:

• Method: Prior to and following an 8–12 hour immersion in SGF, microspheres are weighed [12]. With sustained release, HPMC microspheres displayed a swelling index of 150–200% [13].

• Impact: Increased swelling promotes gel formation but may also result in increased density and decreased buoyancy [12].

4.9 Mucoadhesion Testing

Mucoadhesion is assessed for bioadhesive microspheres:

• In Vitro: Uses a texture analyser to determine the degree of adhesion to the pig stomach mucosa [14]. Adhesion forces of 0.5–1 N/cm² were demonstrated by chitosan microspheres [14].
• Ex Vivo: Evaluates retention on removed stomach tissue in a gastric simulation [14]. 4-hour adhesion was demonstrated by amoxicillin beads [27].
• Tensiometry: Measures the interactions of adhesives with mucin solutions [14].

4.10 Drug-Polymer Interaction Studies

To make sure they are compatible, interactions are evaluated:

• FTIR, or Fourier-Transform Infrared Spectroscopy, uses spectral shifts to identify chemical interactions [15]. Carvedilol microspheres formulated with ethyl cellulose exhibited no noticeable interactions [17].
• Differential Scanning Calorimetry (DSC): Verifies drug stability by analysing thermal properties [15]. The drug's melting point remained unchanged in metformin microspheres [26].
• X-Ray Diffraction (XRD): Verifies the crystallinity of the drug in the polymer matrix [15]. Eudragit® microspheres' amorphous drug forms improved solubility [15].

4.11 In Vitro-In Vivo Correlation (IVIVC)

IVIVC evaluates performance by correlating in vitro dissolution with in vivo pharmacokinetic behaviour [25]:

• Level A Correlation: A direct relationship linking in vitro drug release with in vivo absorption [25].Strong Level A IVIVC was observed in propranolol HCl microspheres [25].
• Mathematical Modelling: Establishes correlations through deconvolution techniques [25]. This guarantees that clinical results are predicted by in vitro tests [25].

These thorough assessment techniques guarantee that floating microspheres fulfil safety, performance, and legal requirements.

5. Applications

Because they can increase bioavailability, prolong gastric retention, and provide controlled drug release, floating microspheres have a wide range of uses. An extended explanation of their therapeutic uses is provided below:

5.1 Drugs with Narrow Absorption Windows

For medications that are mostly absorbed in the stomach or upper small intestine, where extended GRT improves bioavailability, floating microspheres are perfect [26]. Among the examples are:

• Metformin: Used to treat type 2 diabetes, metformin microspheres (such as Glucophage® XR) extended GRT to 6–8 hours, resulting in a 30% increase in bioavailability over traditional tablets [26]. This enhances glycaemic control and lowers the frequency of dosing [26].
• Cimetidine: Cimetidine microspheres, an H2-receptor antagonist for peptic ulcers, demonstrated sustained release at pH 6.8, increasing bioavailability by 20% and lowering gastric irritation [22].
• Levodopa: Levodopa microspheres made using supercritical fluid technology improved absorption and decreased motor fluctuations in Parkinson's disease, extending GRT to five hours [32].
• Riboflavin: A vitamin that is absorbed in the upper gastrointestinal tract, riboflavin microspheres enhanced bioavailability by 25%, thereby bolstering nutritional supplementation [26].

Consistent drug levels are guaranteed by these formulations, which enhances patient compliance and therapeutic results [26].

5.2 Treatment of Gastric Disorders

Floating microspheres are highly effective for localized treatment of gastric conditions by maintaining elevated drug concentrations in the stomach [27]:

• H. pylori Infections: When compared to standard therapy, amoxicillin-loaded floating-bioadhesive beads improved H. pylori eradication rates by 30% by achieving high local concentrations [27]. By focussing on the stomach mucosa, psoralen microspheres, when used in combination therapies, improved antibacterial efficacy [27].
• Peptic Ulcers: Famotidine microspheres reduced acid secretion and aided in ulcer healing by providing sustained release for eight hours [22]. Long-lasting antisecretory effects from ranitidine microspheres improved symptom relief [26].
• Gastritis: Metronidazole microspheres reduced the frequency of dosing and associated side effects by targeting local inflammation and achieving 85% drug release over 10 hours [27].

To optimise local drug action, these applications take advantage of the mucoadhesive and floating qualities [14, 27].

5.3 Controlled Release Systems

By offering sustained drug release, floating microspheres lower the frequency of doses and improve patient compliance [28]:

• Ofloxacin: Used to treat urinary tract infections, ofloxacin microspheres (like Oflin OD®) maintained therapeutic plasma levels while achieving once-daily dosing with 12-hour sustained release [28].
• Propranolol HCl: Propranolol microspheres reduced dosage from twice to once daily for hypertension by extending release to 10 hours [25].
• Trimetazidine: Angina microspheres based on chitosan offered a 10-hour sustained release, enhancing cardiovascular results [14].

Peak-trough fluctuations are minimised by controlled release, which also improves adherence and lowers side effects [28].

5.4 Chronotherapy

For chronotherapeutic applications, floating microspheres synchronise drug release with circadian rhythms [26]:

• Ranitidine: Ranitidine microspheres improved the effectiveness of gastro-oesophageal reflux disease (GERD) by releasing the medication during the night, when acid secretion is at its highest [26].
• Theophylline: Theophylline microspheres improved respiratory function by delivering a sustained release of theophylline during the early morning hours, when symptoms are at their worst [26].
• Nifedipine: To improve cardiovascular control in hypertension, nifedipine microspheres delivered the medication during morning blood pressure spikes [26].

By coordinating drug release with physiological demands, chronotherapy improves therapeutic efficacy [26].

5.5 Local Delivery

Floating microspheres enhance localized drug activity in the stomach, thereby minimizing systemic adverse effects [22].

• Famotidine: Famotidine microspheres reduced acid-related damage to gastric ulcers by maintaining high local concentrations [22].
• Clarithromycin: Targeting the stomach mucosa, clarithromycin microspheres increased the eradication rates of H. pylori when used in triple therapy [27].
• Sucralfate: Sucralfate microspheres enhanced mucosal repair and ulcer prevention by creating a localized protective coating [22].

By lowering systemic exposure, local delivery enhances safety profiles [22].

5.6 Combination Therapies

Floating microspheres can be used to deliver multiple medications for synergistic effects [27]:

• H. pylori Triple Therapy: By releasing amoxicillin, clarithromycin, and proton pump inhibitors (such as omeprazole) in microspheres at the same time, eradication rates were increased by 35% [27].
• Antidiabetic Combinations: Metformin and glipizide microspheres provided dual release profiles that enhanced glycaemic control [26].
• Cardiovascular Therapies: By addressing hypertension and platelet aggregation, propranolol and aspirin microspheres improved cardiovascular outcomes [25].

Combination treatments improve efficacy and streamline regimens [27].

5.7 Theranostic Applications

Theranostics, integrating diagnostic and therapeutic functions, represents an emerging application [32]:

• Diagnostic Agents: By enabling gastric visualisation via X-ray or MRI, microspheres loaded with imaging agents (such as barium sulphate) help diagnose disorders of gastric motility [25].
• Targeted Therapy: Drugs and diagnostic probes are delivered by nanoparticle-integrated microspheres, allowing for real-time tracking of drug release and therapeutic response [32].

Theranostics, by merging diagnostic and therapeutic capabilities, pave the way for personalized medicine [32].

5.8 Paediatric and Geriatric Applications

Special populations are the target of floating microspheres [26]:

• Paediatric: Taste-masked microspheres, such as amoxicillin suspensions, increase palatability and boost children's compliance [27].
• Geriatric: In older patients with dysphagia, smaller microspheres (10–50 µm) improve adherence by reducing swallowing difficulties [26].

By addressing particular needs, these formulations increase their clinical utility [26].

5.9 Veterinary Applications

In veterinary medicine, floating microspheres are being investigated [26]:

• Antibiotics: Amoxicillin microspheres improved treatment efficacy by extending GRT for gastric infections in livestock, such as cattle [27].
• Anthelmintics: Albendazole microspheres provided a sustained release of medication that targeted ruminant stomach parasites [26].

Applications in veterinary medicine improve animal health and lessen the need for frequent treatments [26].

6. Challenges and Future Perspectives

To optimise floating microspheres' therapeutic potential, a number of obstacles must be overcome in their development and use. Future developments offer promising solutions to address these limitations.

6.1 Challenges

• Physiological Variability: Patients' fed/fasted states, pH, and gastric motility differ greatly, which impacts GRT [29]. For example, effervescent system performance is improved under fed-state conditions (pH 2–4), whereas buoyancy may be decreased in fasted states (pH 1-2) because there is less acid available for gas generation [29]. Consistent performance is complicated by inter-patient variations in gastric emptying rates (30–120 minutes in fasted states vs. 2–6 hours in fed states) [29]. Furthermore, conditions such as peptic ulcers or gastroparesis change the dynamics of the stomach, which affects the retention of microspheres [29].
• Scale-Up Limitations: Due to batch-to-batch variability and solvent recovery difficulties, techniques such as emulsion-solvent evaporation have reproducibility problems [30]. At industrial scales, spray drying necessitates exact control over drying parameters (such as feed rate and inlet temperature), which is challenging to achieve [30]. Despite being environmentally friendly, ionotropic gelation has trouble producing beads of consistent size on a large scale [10].
• Drug Stability: Protective coatings or enteric polymers are necessary for acid-sensitive medications (such as proton pump inhibitors), which raises the complexity and expense of formulation [31]. Long-term exposure to stomach acid can break down medication payloads, decreasing their effectiveness [31]. Because biologics (like peptides) are sensitive to preparation conditions like high temperatures or organic solvents, encapsulating them is difficult [31].
• Regulatory Obstacles: Obtaining regulatory approval requires proving reliable in vivo performance across a range of populations [31]. Clinical trials are complicated by variations in gastric pH, motility, and food intake, necessitating in-depth pharmacokinetic and scintigraphy studies [25]. Particularly for new polymers or gas-generating agents, regulatory bodies require strong stability data and proof of safety [31].
• Patient Compliance: Although floating microspheres lower the frequency of doses, their size (1–1000 µm) may have an impact on swallowing or palatability in older or paediatric populations [26]. While tiny microspheres run the risk of premature stomach emptying, large ones can be uncomfortable [26].
• Cost and Accessibility: High-tech methods such as electrospraying or supercritical fluid technology necessitate costly equipment, which restricts their use in environments with limited resources [32]. Widespread adoption is hampered by the additional expense of smart polymers and nanoparticle integration [33].

6.2 Future Perspectives

Future directions seek to use creative methods to address these issues:

• Nanotechnology Integration: Targeting and bioavailability are improved when microspheres and nanoparticles are combined [32]. For instance, by raising the local drug concentration, amoxicillin microspheres loaded with nanoparticles enhanced the eradication of H. pylori [27]. Drugs that are sensitive to acid can be protected by nano-encapsulation, which eliminates the need for intricate coatings [32]. Hybrid nano-micro systems for dual-release profiles (immediate and sustained) are the goal of future research [32].
• Smart Polymers: Adaptive release is made possible by stimuli-responsive polymers, such as those that are pH-, temperature-, or enzyme-sensitive [33]. While pH-sensitive Eudragit® targets particular GIT regions, PNIPAAm-based microspheres modify release according to gastric temperature [33]. Multi-stimuli-responsive polymers that react to markers of inflammation or gastric enzyme activity are among the upcoming innovations that will improve the accuracy of disease-specific therapies [33].
• Personalised Medicine: Formulations are more effective when they are tailored to the unique gastric conditions of each patient (e.g., pH, motility, disease state) [34]. Customised microsphere designs are made possible by real-time gastric data provided by sophisticated diagnostic instruments such as wireless motility capsules [34]. By using patient profiles to predict the best formulations, machine learning models can minimise development trial-and-error [34].
• Sustainable Production: Environmental impact and solvent consumption are decreased by eco-friendly techniques such as supercritical fluid technology [32]. Biodegradable polymers and solvent-free procedures are examples of future developments that will improve sustainability [32]. Reproducibility for industrial applications may be enhanced by scaling ionotropic gelation using automated systems [10].
• Artificial Intelligence (AI): AI-powered optimisation can forecast ideal release profiles, preparation circumstances, and polymer ratios [34]. In order to reduce experimental expenses and enhance reproducibility, machine learning models examine formulation data [34]. Additionally, AI can mimic in vivo performance, which lessens the need for expensive clinical trials [34].
• Advanced Imaging and Monitoring: To track the performance of microspheres in specific patients, real-time imaging methods such as MRI and gamma scintigraphy can be incorporated into clinical practice [25]. Ingestable sensors to monitor GRT and drug release are among the upcoming innovations that will allow for dynamic therapy modifications [34].
• Combination Therapies: By delivering several medications at once, floating microspheres can treat complicated illnesses like H. pylori infections that call for triple therapy (e.g., amoxicillin, clarithromycin, proton pump inhibitors) [27]. For theranostic applications, future formulations might include diagnostic agents or synergistic drug combinations [32].
• Regulatory Streamlining: Creating standardised GRDDS testing procedures can make regulatory approval easier [31]. Comprehensive clinical studies can be avoided by establishing guidelines for in vitro-in vivo correlations through cooperation between academia, industry, and regulators [31].
• Patient-Centric Design: By creating taste-masked powders or suspensions, microspheres can be made more palatable for both elderly and paediatric patients [26]. By reducing particle size without sacrificing buoyancy, microencapsulation techniques can improve patient comfort [26].

CONCLUSION

Floating microspheres have transformed GRDDS by offering prolonged gastric retention, controlled drug release, and enhanced bioavailability. Advances in preparation techniques, polymer selection, optimization of formulation variables, innovative approaches, evaluation methods, and diverse applications ensure their therapeutic versatility. Despite challenges, innovations in nanotechnology, smart polymers, and AI promise to enhance their clinical potential across medical and veterinary applications.

REFERENCES

1. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235–259.
2. Soppimath KS, et al. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Metab Rev. 2001;33(2):149–60.
3. Arora S, et al. Floating Drug Delivery Systems: A Review. AAPS PharmSciTech. 2005;6(3):E372–E390.
4. Streubel A, et al. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3(2):217–33.
5. Choi BY, et al. Preparation of alginate beads for floating drug delivery system: effect of CO2 gas-forming agent. J Control Release. 2002;84(3):115–123.
6. Firke SN, et al. A Review on Floating Microspheres as Gastro-retentive Drug Delivery System. Current Overview on Pharmaceutical Science. 2022;1:145–162.
7. Kawashima Y, et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci. 1992;81(2):135–140.
8. Kawashima Y, et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci. 2016;81(2):135–140.
9. Soppimath KS, et al. Nanospheres with PLGA for drug delivery. J Control Release. 2001;70(3):281–291.
10. Ikechukwu UR, et al. Development and evaluation of ritonavir hollow microballoons for floating drug delivery. Universal J Pharm Res. 2017;2(2):30–34.
11. Hwang KM, et al. Highly porous cilostazol gastroretentive tablets using sublimation technique. Int J Pharm. 2016;334:35–41.
12. Kim S, et al. Pregabalin gastroretentive tablets with super-disintegrants. J Control Release. 2016;234:45–53.
13. Gunda RK, et al. Formulation Development and Evaluation of Gastro Retentive Drug Delivery Systems-A Review. J Pharm Res. 2017;11(2):167–178.
14. El-Nahas H, et al. Chitosan-based floating microspheres of trimetazidin dihydrochloride. Indian J Pharm Sci. 2011;73(4):397.
15. Choudhury PK, et al. Cellulose acetate microspheres as floating depot systems. Drug Dev Ind Pharm. 2008;34(4):349–54.
16. Raza A, et al. Zein-based floating tablets with sublimating agents. J Pharm Sci. 2016;105(9):2765–2773.
17. Nila MV, et al. Floating microspheres of carvedilol as gastro retentive drug delivery system: 3² full factorial design and in vitro evaluation. Drug Deliv. 2014;21(2):110–7.
18. Nila MV, et al. Optimization of carvedilol microspheres. J Microencapsul. 2009;26(5):432–43.
19. Patil SB, et al. Development and evaluation of alginate mucoadhesive microspheres. J Microencapsul. 2009;26(5):432–43.
20. Yadav VD, et al. Formulation and Evaluation of Floating Beads of Norfloxacin. IOSR J Pharm. 2016;6(9):07–13.
21. Mukund JY, et al. Floating microspheres: a review. Braz J Pharm Sci. 2012;48:17–30.
22. Srivatava AK, et al. Floating Microspheres of Cimetidine: Formulation, Characterization and In Vitro evaluation. Acta Pharm. 2005;55:277–285.
23. Pujara ND, et al. Floating Microspheres: A Novel Approach for Gastro Retention. Res J Pharm Tech. 2012;5(2):883–886.
24. Kumar K, et al. Development and evaluation of floating microspheres of curcumin. Trop J Pharm Res. 2012;11(5):713–9.
25. Meka VS, et al. Statistical optimization of propranolol HCl floating tablets. Daru. 2012;20(1):21.
26. Kotreka UK, et al. Gastroretentive floating drug-delivery systems: a critical review. Crit Rev Ther Drug Carrier Syst. 2011;28(1):47–99.
27. Thombre NA, et al. Floating-bioadhesive gastroretentive beads of amoxicillin trihydrate. Drug Deliv. 2016;23(2):405–19.
28. Gunda RK, et al. Floating drug delivery system- a review. J Pharm Res. 2017;11(2):167–178.
29. Klausner EA, et al. Expandable gastroretentive dosage forms. J Control Release. 2003;90:143–162.
30. Asija R, et al. Solvent evaporation matrix erosion method for floating microsphere development. J Drug Discov Ther. 2014;2(21):24–29.
31. Prinderre P, et al. Advances in gastro retentive drug-delivery systems. Expert Opin Drug Deliv. 2011;8:1189–1203.
32. Haimhoffer Á, et al. Micro and nanoparticles for H. pylori treatment. Int J Pharm. 2020;29(5):3613–3627.
33. Omidian H, et al. Advances in superporous hydrogels. J Control Release. 2005;102:3–12.
34. Lopes CM, et al. Gastroretentive drug delivery systems: current developments in novel system design. Curr Drug Deliv. 2009;6:451–460.
35. Boddupalli BM, et al. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res. 2010;1(4):381–387.
36. Das S, et al. Lipid-based nanoparticles in gastroretentive drug delivery. Int J Pharm. 2021;598:120–129.
37. Zhang Y, et al. Porous microspheres for controlled drug delivery. J Control Release. 2018;282:90–100.
38. Xu J, et al. 3D printing for gastroretentive drug delivery systems. Adv Drug Deliv Rev. 2022;180:114–125.
39. Liu X, et al. Microfluidic synthesis of monodisperse microspheres. Biomaterials. 2021;275:120–130.
40. Chen Z, et al. Stimuli-responsive polymers for gastroretentive delivery. J Pharm Sci. 2023;112(5):1050–1060.
41. Wang H, et al. Self-assembling microspheres for drug delivery. Nanomedicine. 2022;17(4):250–265.
42. Li Q, et al. Magnetic-responsive microspheres for targeted delivery. Int J Pharm. 2023;615:121–135.
43. Kim M, et al. Bioinspired microspheres for gastroretentive systems. J Mater Chem B. 2023;11(8):1800–1815.